Keynote: Meet the Outliers in cancer

Despite recent therapeutic breakthroughs, Cancer remains a formidable challenge in modern medicine, with certain types proving almost insurmountable. But one company is out to change that. And they’re flipping the script on Cancer research.Rather than focus on the 99% of patients who die from those most lethal cancers, Cure51 has a new approach. Focus on the 1% of patients who actually survive and defy all odds: the Outliers.A paradigm shift in cancer research, Cure51 studies miraculous survivors biology to uncover new therapeutic targets. Using advanced molecular profiling, Cure51 aims to make every cancer patient an Outlier, improving survival rates and quality of life.Join Nicolas Wolikow, Founder & CEO at Cure51 who will discuss how their comprehensive and multimodal database of 1300+ Outliers can be used to revolutionise the standard of care therapies for all.He’ll be joined by T V Ajithkumar (MD FRCP FRCR MBA), Clinical Director Laboratories at Cambridge University Hospitals, and Jean-Luc Gonfond, a 12 years exceptional survivor of Pancreatic Cancer (PDAC).Watch live on the main stage and get ready for a discussion like no other.